UCB wins FDA approval for ZILBRYSQ autoinjector. UCB stock carries EUR 39.0 billion market value

Published on 10/19/2026 at 09:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

FDA approval expands UCB's ZILBRYSQ option. UCB stock costs EUR 204.80 on October 19, 2026, while H1 revenue reached EUR 4.27 billion.

FDA approval strengthens product access

On October 16, 2026, FDA approval covered UCB's ZILBRYSQ autoinjector option.
UCB reported EUR 4.27 billion in revenue for the first half of 2026.
UCB stock traded at EUR 204.80 at 9:37 a.m. CEST at Lang & Schwarz on October 19, 2026.

Flatlay mit Aktienzertifikat, ISIN-Karte BE0003739530, Stethoskop und Molekülmodell auf weißem Untergrund — UCB S.A. mit ISIN BE0003739530 als Flatlay: Aktienzertifikat, ISIN-Karte, Molekülmodell und Laborutensilien arrangiert, Illustration mit AI erstellt.

UCB stock (ISIN BE0003739530) was trading at EUR 204.80 at Lang & Schwarz on October 19, 2026 at 9:37 a.m. CEST. FinanzNachrichten reported on October 16, 2026 that the U.S. Food and Drug Administration had approved a once-daily ZILBRYSQ autoinjector for certain adults with generalized myasthenia gravis.

FDA approval adds a 2027 product step

The decision expands ZILBRYSQ beyond its existing prefilled syringe format. UCB expects the autoinjector to become commercially available in the first quarter of 2027, giving the announcement a concrete commercialization date.

What powers the next growth phase?

UCB's first-half performance provides the financial backdrop. On its investor page, UCB reports revenue of EUR 4.27 billion for the first half of 2026. BIMZELX sales reached EUR 1.52 billion, while ZILBRYSQ sales totaled EUR 139 million in the same period. The product mix matters because the newer medicines must offset erosion in older therapies over time.

The recent chronology shows how the portfolio is developing. On September 9, 2026, UCB received a U.S. FDA Breakthrough Therapy Designation for CIMZIA in pregnant women with antiphospholipid syndrome, according to Simply Wall St. On September 30, 2026, UCB presented EADV data supporting earlier use of BIMZELX, as listed by 6ix. The October 16 approval was the latest event and included the first-quarter 2027 availability target.

Next reporting date is February 2027

UCB is scheduled to report fiscal year 2026 results on February 25, 2027, according to Simply Wall St. That release will show whether the first-half revenue base and newer product launches are translating into the full-year outcome.

Stock price and investor perspective

UCB's market value stood at EUR 39.01 billion at the October 16, 2026 close, while the latest company figures point to BIMZELX and ZILBRYSQ as measurable commercial drivers. The FDA decision adds a product-access milestone ahead of the next full-year reporting date.

The further course of trading is shown by the continuously updated real-time quote of UCB stock.